Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Guangdong General Hospital · Guangdong Academy of Medical Sciences · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,972
total citations
- FWCI
- 165.06
- Percentile
- 100%
- References
- 36
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- Afatinib
- Medicine
- Gemcitabine
- Internal medicine
- Oncology
- Lung cancer
- Pemetrexed
- Regimen
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.